FunGP – Functional Genomics and Proteostasis Lino Almeida
FunGP – Functional Genomics and Proteostasis
The main goal of the
Functional Genomics and Proteostasis Group
is to to understand human diseases and achieve drug discovery using functional genomics and systems approaches along with molecular and cell biology approaches.
FunG&P is organized into five research labs, each headed by a PI. Each team explores independent scientific aims but with common interests and contributing to 3 out of the 4 major thematic lines of BioISI. Three of the groups have an international reputation in the frontline research of the competitive field of the monogenic disease Cystic Fibrosis, while the remaining two are leaders in signal transduction in cancer and pharmaco-resistance in malaria. The group also includes two Visiting Professors with double-affiliation to non-Portuguese institutions.
The major research topics of the Fun-GP group are focused on molecular and systems biology of Cystic Fibrosis (CF), cancer and malaria; studies of membrane proteins associated with human diseases; pharmacogenomics and drug development; biomarker identification; biodevices for point-of care medicine, diagnosis and prognosis.
Specific lines of interest include: 1) novel cellular epithelial models for CF studies; 2) molecular and cellular mechanisms of quality control of the endoplasmic reticulum and secretory traffic of the CFTR protein; 3) characterization of signal transduction pathways influencing oncogenic reprogramming of epithelial cells; 4) influence of host-pathogen genomes on the efficacy of drugs with a strong interest in drug transporter proteins; 5) identification of drug targets and drug screens target screens in cancer and chronic diseases
FUN-GP members are mainly associated with BioISI’s thematic line of Biomedicine but cooperative projects are being developed for integrative research within the thematic lines of Biological Physics (for biodevice development) and Bioinformatics & Modelling.
PI’s: M D Amaral | Carlos Farinha | Paulo Matos | Cláudio Gomes | …
Post Docs: Hugo Botelho| Ines Pankonien | Susana Igreja | Patrícia Barros | Sónia Leal | Bárbara Henriques
PhD Students: Joana Lérias (BioSys)| Sara Canato (BioSys)| Nikhil Awatade (BioSys)| Luís Sousa (BioSys)| João Santos (BioSys)| Madalena Pinto (BioSys)| Daniel Cruz (BioSys)| Margarida Quaresma (BioSys)| Ana Matos (BioSys)| Joana Cristovão | Tânia Lucas | Verónica Felício
Technicians: José Múrias
Amaral MD (2015) Novel Personalized Therapies for Cystic Fibrosis: Treating the Basic Defect in All CF Patients. J Intern Med 277: 155-66. PMID
Botelho HM, et al (2015) Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery. Sci Rep 5: 9038. PMID
Farinha CM, Sousa M, Canato S, Schmidt A, Uliyakina I, Amaral MD (2015) Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect 3: e00152 PMID
Leal, S.S. and C.M. Gomes (2015). Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. Front Cell Neurosci, 2015. 9: p. 225. PMID
Loureiro CA, et al (2015) A NHERF1 PDZ domain switch retains rescued F508del-CFTR at the cell surface by preventing CHIP recruitment. Sci Signal. 8(377), ra48. Doi: 10.1126/scisignal.aaa1580. PMID